Robert E. Landry - EVP Finance CFO at Regeneron Pharmaceuticals, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
EVP Finance CFO
Stock Symbol
REGN on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

Robert E. Landry - trading volume in the past year for Regeneron Pharmaceuticals, Inc.

Holdings reported by Robert E. Landry for Regeneron Pharmaceuticals, Inc.

Class Num Shares Value Price $ Report Date Ownership Underlying Class Underlying Amount
Common Stock 23,693 $22.7 M $956.65 Feb 2, 2024 Direct
Common Stock 270 $252 K $934.71 Feb 2, 2024 By 401(k) Plan
Non-Qualified Stock Option (right to buy) 11,787 Feb 2, 2024 Direct Common Stock

Transactions reported by Robert E. Landry for Regeneron Pharmaceuticals, Inc.

Sym Class Transaction % Value $ Price $ Shares Shares After Date Ownership